Early and late outcome of cardiac surgery in patients with liver cirrhosis

Farzan Filsoufi, Sacha P. Salzberg, Parwis B. Rahmanian, Thomas D. Schiano, Hussien Elsiesy, Anthony Squire, David H. Adams – 10 April 2007 – Liver cirrhosis is a major risk factor in general surgery. Few studies have reported on the outcome of cardiac surgery in these patients. Herein we report our recent experience in this high‐risk patient population according to the Child‐Turcotte‐Pugh classification and Model for End‐Stage Liver Disease (MELD) score.

Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: A case‐control study

Sébastien Dharancy, Jeanne Boitard, Thomas Decaens, Géraldine Sergent, Emmanuel Boleslawski, Christophe Duvoux, Claire Vanlemmens, Carole Meyer, Jean Gugenheim, François Durand, Olivier Boillot, Nicole Declerck, Alexandre Louvet, Valérie Canva, Olivier Romano, Olivier Ernst, Philippe Mathurin, François René Pruvot – 10 April 2007 – Supraselective transarterial chemoembolization (STACE) more efficiently targets chemotherapy delivered via the feeding arterial branches of the tumor than does conventional transarterial chemoembolization (TACE).

Distinct effects of surgical denervation on hepatic perfusion, bowel ischemia, and oxidative stress in brain dead and living donor porcine models

Markus Golling, Cosima Jahnke, Hamidreza Fonouni, Rezvan Ahmadi, Renate Urbaschek, Raoul Breitkreutz, Peter Schemmer, Thomas W. Kraus, Martha M. Gebhard, Markus W. Büchler, Arianeb Mehrabi – 29 March 2007 – The liver function and perfusion following brain death is mainly influenced by the sympathetic nerves and hormones. We examined the specific influence of surgical liver denervation on systemic and hepatic perfusion parameters, bowel ischemia and oxidative stress in hemodynamically stable BD and control (living donor [LD]) pigs.

Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver

Paul P.C. Poyck, Ruurdtje Hoekstra, Albert C.W.A. van Wijk, Chiara Attanasio, Fulvio Calise, Robert A.F.M. Chamuleau, Thomas M. van Gulik – 29 March 2007 – The selection of a cell type for bioartificial liver (BAL) systems for the treatment of patients with acute liver failure is in part determined by issues concerning patient safety and cell availability. Consequently, mature porcine hepatocytes (MPHs) have been widely applied in BAL systems. The success of clinical BAL application systems is, however, largely dependent on the functionality and stability of hepatocytes.

B‐cell surface marker analysis for improvement of rituximab prophylaxis in ABO‐incompatible adult living donor liver transplantation

Hiroto Egawa, Katsuyuki Ohmori, Hironori Haga, Hiroaki Tsuji, Kimiko Yurugi, Aya Miyagawa‐Hayashino, Fumitaka Oike, Akinari Fukuda, Jun Yoshizawa, Yasutsugu Takada, Koichi Tanaka, Taira Maekawa, Kazue Ozawa, Shinji Uemoto – 29 March 2007 – Although the effectiveness of rituximab has been reported in ABO blood group (ABO)‐incompatible (ABO‐I) organ transplantation, the protocol is not yet established.

Risk factors for invasive aspergillosis in living donor liver transplant recipients

Makoto Osawa, Yutaka Ito, Toyohiro Hirai, Rie Isozumi, Shunji Takakura, Yasuhiro Fujimoto, Yoshitsugu Iinuma, Satoshi Ichiyama, Koichi Tanaka, Michiaki Mishima – 29 March 2007 – Invasive aspergillosis (IA) is a severe complication of liver transplantation. Risk factors for IA after deceased donor liver transplantation (DDLT) have been presented in several reports, but are not well established for living donor liver transplant recipients. Here, a retrospective case‐control study was performed.

Subscribe to